
























1352Trends of Hematopoietic Stem Cell Transplantation
in the Eastern Mediterranean Region, 1984-2007
Syed O. A. Ahmed,1 Ardeshir Ghavamzadeh,2 Syed Z. Zaidi,3 Helen Baldomero,4
Marcelo C. Pasquini,5 Fazal Hussain,1 Kamran Alimoghaddam,2 Fahad Almohareb,1
MouhabAyas,1 AmirHamidieh,2HossamK.Mahmoud,6 Alaa Elhaddad,6 Tarek BenOthman,7
Abdelrahman Abdelkefi,7 Mahmoud Sarhan,8 Fawzi Abdel-Rahman,8 Salman Adil,9
Salam Alkindi,10 Ali Bazarbachi,11 Said Benchekroun,12 Dietger Niederwieser,13
Mary Horowitz,5 Alois Gratwohl,4 Hassan El Solh,1 Mahmoud Aljurf1Hematopoietic stem cell transplantation (HSCT) activity was surveyed in the 9 countries in theWorld Health
Organization Eastern Mediterranean region that reported transplantation activity. Between the years of 1984
and 2007, 7933 transplantations were performed. The number of HSCTs per year has continued to increase,
with a plateau in allogeneic HSCT (allo-HSCT) between 2005 and 2007. Overall, a greater proportion of
transplantations were allo-HSCT (n 5 5761, 77%) compared with autologous HSCT (ASCT) (n 5 2172,
23%). Of 5761 allo-HSCT, acute leukemia constituted the main indication (n5 2124, 37%). There was a sig-
nificant proportion of allo-HSCT for bone marrow failures (n 5 1001, 17%) and hemoglobinopathies (n 5
885, 15%). The rate of unrelated donor transplantations remained low, with only 2 matched unrelated donor
allo-HSCTs reported. One hundred umbilical cord blood transplantations were reported (0.017% of allo-
HSCT). Peripheral blood stem cells were the main source of graft in allo-HSCT, and peripheral blood
stem cells increasingly constitute the main source of hematopoietic stem cells overall. Reduced-intensity
conditioning was utilized in 5.7% of allografts over the surveyed period. ASCT numbers continue to increase.
There has been a shift in the indication for ASCT from acute leukemia to lymphoproliferative disorders
(45%), followed by myeloma (26%). The survey reflects transplantation activity according to the unique
health settings of this region. Notable differences in transplantation practices as reported to the European
Group for Blood and Marrow Transplantation over recent years are highlighted.
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Hematopoietic stem cell transplantation (HSCT)
is a potentially curative therapeutic modality for
many hematologic and, increasingly, nonhematologic
conditions. The last few decades have witnessed sig-
nificant developments in conditioning techniques,
better donor selection, and posttransplantation care,
all of which have contributed to improvements in
outcomes [1].
Data pertaining to transplantation are captured
by a number of international registries, including the
European Group for Blood and Marrow Transplanta-
tion (EBMT), International Bone Marrow Transplant
Registry,World BoneMarrowTransplant Group, and
Asia-Pacific Bone Marrow Transplant Group, among
others. In addition to informing the transplant commu-
nity of outcomes, risk factors, and efficacy of HSCT in
given diseases, the information thus obtained also assists
transplantation physicians in planning the various
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ing research [2].
The Eastern Mediterranean Blood and Marrow
Transplantation (EMBMT) group was conceived in
2007, and represents the 9 countries that have an active
transplant program from among the 17 East Mediter-
ranean Regional Organization (EMRO) nations as de-
fined by the World Health Organization (WHO)
(Table 1) [3]. We have recently reported on special is-
sues pertaining to HSCT in the region such as the
prevalence of hemoglobinopathies, cytomegalovirus
seropositivity, prevalence of hepatitis B, and resource
limitations. The report also provided a regional over-
view of economic status in terms of gross national in-
come (GNI), transplantation rates, and team density
[4]. In this report, we present a survey of HSCT activ-
ity pertaining to allogeneic HSCT (allo-HSCT) and
autologous HSCT (ASCT) activity in the region
over a 24-year period as reported to the EMBMT,
and provide a comparison with transplantation activity
reported to EBMT for 2007.METHODS
The participating centers were identified by means
of a database that was established following initial
meetings between teams. An active program was iden-
tified as one that consistently performed$5 transplan-
tations per year for at least 3 consecutive years. The
EMBMT holds a directory of participating centers,
with the names and addresses of participating centers
and named transplantation physicians with their con-
tact details.
An electronic data capture sheet was sent via e-mail
to each of these members where the following fields of
information were sought for allo-HSCT and ASCT
transplants: indication of transplant (including stage of
disease); conditioning in allo-HSCT (conventional
versus reduced-intensity conditioning [RIC]); andTable 1. Overall Transplant Activity in Countries of the Eastern M
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Total number of transplantations:
ASCT indicates autologous hematopoietic stem cell transplantation; allo-HSC
Mediterranean Blood and Marrow Transplantation; KSA, Kingdom of Saudi Ar
*EMRO countries that do not have a transplant program, or that were not rep
Afghanistan, Bahrain, Djibouti, Iraq, Kuwait, Libya, Qatar, Somalia, Sudan, Syriasource of stem cells (related bone marrow [BM] versus
related peripheral blood stem cells [PBSC] versus
umbilical cord blood [UCB] versus matched unrelated
donor [MUD]).
The data were sought for each year since the incep-
tion of the respective transplant program. For trans-
plant by indication, only the first transplantation was
reported to avoid rereporting.
Data from different participating centers within
a country were aggregated to present national data.
The data were tabulated at the office of the EMBMT.
No remuneration was offered to participating centers.
The EBMT Group Activity Survey was utilized as
a template for analysis of the activity data, and supple-
mentary datawas obtained fromEBMTasneeded.The
reported data was alsomatched with submitted data for
theCenter for International Blood andMarrowTrans-
plant Research (CIBMTR) for CIBMTR reporting
centers. A comparison was made between transplant
practices in the EMBMT survey for 2007 and HSCT
activity reported to the EBMT for the same year.RESULTS
Overall Transplant Activity
Countries identified with an active transplant pro-
gram were Egypt, Iran, Jordan, Lebanon, Morocco,
Oman, Pakistan, Saudi Arabia, and Tunisia. Of 17 ac-
tive teams in 9 countries, completed data capture
sheets were received from all except 2 teams (Makassed
General Hospital, Lebanon, and Bismilah Taqi Insti-
tute, Pakistan). Information on the type of conditioning
was not available from 2 countries (Tunisia and Iran).
Information on the source of stem cells was incomplete
from 2 countries (Pakistan and Tunisia).
A total of 7933 first transplantations were reported
between the periods of 1984 and 2007, of which 2172
(27%) were ASCTs and 5761 (73%) were allo-HSCTs













T, allogeneic hematopoietic stem cell transplantation; EMBMT, Eastern
abia.
orted to the EMBMT to have performed $5 HSCT for $3 years were:
, United Arab Emirates, Yemen.
1354 Biol Blood Marrow Transplant 17:1352-1361, 2011S. O. A. Ahmed et al.activity from 12 transplantations in 1984 to 1097 in
2007 (Figure 1). Over the survey period, the mean
year-on-year increase in transplant activity was 24%,
with a significant increase in activity in the period
1996 to 2007.
Allogeneic Transplantation
A total of 5761 allo-HSCT procedures were per-
formed, starting with 12 in 1984 to 684 in 2007. Except
for Morocco, where all reported transplantations were
ASCT, and Tunisia, where 50% of transplantations
were ASCT, in the remaining countries the majority
of the transplants were allo-HSCT (Figure 2). There
was significant variation in total allo-HSCT number
between countries and in the increase in numbers
over the 24-year period (Table 1 and Figure 3). Over
2005 to 2007, overall allo-HSCT numbers showed
a plateau, although numbers in Iran and Pakistan con-
tinue to rise.
Indication for Allogeneic Transplantation
Of the 5761 allo-HSCTs, a major indication was
acute leukemia (n5 2124, 36.8%). Acute myeloid leu-
kemia (AML) accounted for 1260 (21%) allo-HSCTs
with 924 transplantations in first complete remission
(CR1) (16%) and 336 (5%) beyond CR1. Acute lym-
phoblastic leukemia in all stages accounted for 864
(15%) allo-HSCTs. Other major indications were
bone marrow failure, both congenital and acquired
(n 5 1001, 17%), followed by chronic myeloid leuke-
mia (CML) in both chronic phase and beyond (n 5
948, 16%). There was a recent reduction in allo-
HSCT for CML (Figure 4). There was a significant
proportion of patients who received transplants for he-
moglobinopathies (n 5 885, 15%), especially in IranFigure 1. Trends in total numbers of autologous and allogeneic transplantatio
ogous hematopoietic stem cell transplantation; ALLO-HSCT, allogeneic hemaand Egypt, which both have a high carrier rate of
ß-thalassemia [5,6]. Other diagnoses were the
indication for allo-HSCT in the remaining 15% of re-
ported cases, and indications remained relatively stable
over time (Figure 5).
Conditioning Regimes
Conditioning information was sought for all allo-
HSCTs. Of the 8 countries performing allo-HSCTs,
data were returned from 5. Of all 5761 allo-HSCTs,
3483 (60.4%) were performed with conventional con-
ditioning regimes, and 333 (5.7%) utilized RIC. Con-
ditioning intensity was unknown in 1945 (33.7%)
allografts.
RIC transplants, although not performed before
1999, are being performed increasingly and accounted
for conditioning in 51 transplants in 2007 (Figure 6).
Over the survey period, the mean annual proportion
of RIC HSCT was 13.4% of allo-HSCTs where con-
ditioning information was available.
Stem Cell Source for Allogeneic Transplants
The sources of hematopoietic stem cells for allo-
HSCTs were peripheral blood stem cells (PBSCs)
(2688 allo-HSCTs, 47%) followed by BM (2523
allo-HSCTs, 44%). The source was unknown in 478
(8.2%) allo-HSCTs. There was a shift from BM to
PBSCs, especially in the years after 2000 (Figure 7).
There were variations between countries in the use
of BM versus PBSCs. In the Kingdom of Saudi Arabia,
related BM was used in 1815 (86%) of allo-HSCTs
over the surveyed period, while in Egypt, BM was
the source in only 31 (3%), with PBSCs being used
in 97% of allo-HSCTs. In the other countries sur-
veyed, PBSCs were used more frequently than BM.n procedures, 1984 to 2007. Abbreviations: AUTO SCT indicates autol-
topoietic stem cell transplantation.
Figure 2. Overall autologous and allogeneic hematopoietic stem cell transplantation numbers, 1984 to 2007, by country. Abbreviations: KSA indicates
Kingdom of Saudi Arabia; ALLO-HSCT, allogeneic hematopoietic stem cell transplantation; ASCT, autologous stem cell transplantation.
Biol Blood Marrow Transplant 17:1352-1361, 2011 1355Trends of HSCT in the Eastern Mediterranean RegionUCB transplantations were first performed in the
region in 1998. Overall, 100 transplantations (2% of
allografts) have been performed with UCB as a source
of stem cell. There were 6 coinfusions of BM with
PBSCs (5/6) and UCB (1/6). Only 2 (0.003%) non-
UCB MUD allo-HSCTs were reportedly performed.Autologous Transplantation
A total of 2172 ASCT procedures were performed
during the period 1985 to 2007. There was an increase
in procedures from 1 in 1985 to 413 in 2007 withFigure 3. Trends in total numbers of first allo-HSCTactivity, 1984 to 2007,
allogeneic hematopoietic stem cell transplantation; EMBMT, Eastern Mediterraa continuing increase in transplantation procedures
year-on-year. There was a 25% increase in ASCT ac-
tivity from 2006 to 2007 (Figure 1).Indication for Autologous Transplantation
Of the 2172 total ASCTs, themain indications were
myeloma (n5 557, 25.6%), Hodgkin’s lymphoma (n5
539, 25%), non-Hodgkin lymphoma (n5 451, 20.7%),
and AML (n5 326, 15%), with other indications com-
prising the remaining 14% of ASCTs. There was a re-
duction in the proportion of ASCTs performed forby country as reported to EMBMT. Abbreviations: Allo-HSCT indicates
nean Blood and Marrow Transplantation; KSA, Kingdom of Saudi Arabia.
Figure 4. Trends in allo-HSCT for CML in first chronic phase (CP1) and beyond (.CP1). Abbreviations: Allo-HSCT indicates allogeneic hematopoietic
stem cell transplantation; CML, chronic myeloid leukemia.
1356 Biol Blood Marrow Transplant 17:1352-1361, 2011S. O. A. Ahmed et al.acute leukemia and myelodysplasia from a median of
70.5% (range: 50%-100%) in the years 1988 to 1996,
to 21% (10%-46%) in the years 1997 to 2007 (Figure 8).Figure 5. Trends in allo-HSCT in the Eastern Mediterranean region by disease
Abbreviations: AML indicates acute myeloid leukemia; ALL, acute lymphoblasti
myeloproliferative disorder; LPD, lymphoproliferative disorders; BMF, bone mA total of 32 ASCTs were performed between
the years of 1996 and 2001 for breast cancer; none
were reported for this indication after 2001. ASCTindication, 1984 to 2007, expressed as percentage of annual transplants.
c leukemia; CML, chronic myeloid leukemia; MDS, myelodysplasia; MPD,
arrow failure.
Figure 6. Total numbers of allo-HSCT by conditioning. Abbreviations: Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; EM,
Eastern Mediterranean; RIC, reduced-intensity conditioning; UK, unknown.
Biol Blood Marrow Transplant 17:1352-1361, 2011 1357Trends of HSCT in the Eastern Mediterranean Regionprocedures were performed in a total of 134 (6%) cases
of other nonhematologic malignancies.
Stem Cell Source for Autologous Transplants
PBSC was the main source of stem cells in 1875
(86%) ASCTs; BM was the source for 223 (10%)
ASCTs, and in 11 (1%) both PBSCs and BM stem cells
were co-infused. The source of stem cells was not
known in 65 (3%) ASCTs.Figure 7. Trends in stem cell source for allo-HSCTs, 1984 to 2007. Abbrevia
cord blood; MUD, matched unrelated donor.DISCUSSION
This is the first activity survey of the EMBMT,
which presents the analysis of transplantation activity
in the WHO EMRO region between the years 1984
and 2007. Individual country reports have previously
been published, highlighting each country’s unique
HSCT setting. The data here illustrate the increasing
transplantation activity in the region over the years andtions: BM indicates bone marrow; PB, peripheral blood; UCB, umbilical
Figure 8. Trends in ASCT in the Eastern Mediterranean region by disease indication, 1984 to 2007, expressed as percentage of annual transplants.
Abbreviations: AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplasia;
MPD, myeloproliferative disorder; PCD, plasma cell disorders; NHL, non-Hodgkin lymphoma; HD, Hodgkin’s disease; CLL, chronic lymphocytic leuke-
mia; PLL, prolymphocytic leukemia.
1358 Biol Blood Marrow Transplant 17:1352-1361, 2011S. O. A. Ahmed et al.the trends in indication for HSCT conditioning prac-
tices and sources of stem cells.
The overall number of transplantations in the
EMRO region of 7933 over a span of 24 years is signif-
icantly lower as a cumulative number compared with
annual numbers in Western Europe over a single
year. In 2003, 17,020 first HSCTs were performed in
15 Western European countries with a population of
381 million, equating to 446 HSCTs per 10 million
population [7]. In comparison, in the 9 EMBMT
countries with a collective population of 367 million
in the same year [8], 704 HSCTs were performed, or
19 per 10 million population. However, transplanta-
tion numbers, especially ASCTs, in the region con-
tinue to increase at a steady rate and have yet to
plateau, although transplantation rates remain low [4].
Factors that may contribute to regional differences
in HSCT activity have been elucidated [9,10]. Allo-
HSCT is an expensive procedure, and various factors
can affect total cost [11]. GNI, team density, and
healthcare expenditure reportedly have an impact on
transplantation numbers [12].
Although there appears to be a degree of correla-
tion between GNI and stem cell transplantation per
10 million inhabitants, this does not always hold
true, and various other unexplained factors are likely
to contribute to a higher or lower than expected
HSCT rate in any given country (Figure 9). There
may be a number of reasons for discrepancies in
transplantation rates in countries with similar GNI,including infrastructure and sociopolitical factors
[9,13]. Data for patients referred overseas for HSCT
were not available for the purposes of the study,
although such referral practices may go some way in
fulfilling transplantation requirements, especially in
the few countries with a higher GNI.Allo-HSCT versus ASCT
There has been a steady increase in the number of
allo-HSCTs being performed with a mean year-on-
year rise of 20%. There was no significant overall
increase over the period 2005 to 2007, possibly as a re-
flection of the saturation of available services or other
local factors.
The majority (73%) of all transplantation proce-
dures over the survey period were allo-HSCT, and
this was true for each year surveyed (mean: 74%,
range: 63%-100%). In 2007, 63% of procedures
were allo-HSCT, representing a gradual trend toward
an increase in the proportion of ASCTs. This is in con-
trast to activity reported from EBMT, where in 2007
ASCTs comprised the majority of transplantation ac-
tivity with 15,491 (61%) ASCTs versus 10,072 (39%)
allo-HSCTs [14]. Data from the United States as re-
ported to CIBMTR also demonstrate an excess of
ASCT over allo-HSCT [15]. A possible explanation
for the excess allo-HSCTs may be that the Eastern
Mediterranean region consists of communities of large
families with high population growth, which certainly
Figure 9. Correlation of gross national income (US$) per capita in 2007 of countries reporting to EMBMTagainst transplant rates. Abbreviations: SCT
indicates stem cell transplant; GNI, gross national income; KSA, Kingdom of Saudi Arabia.
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ling donor. Demographic information of the trans-
planted population in the EMRO region would be
required to investigate this regional difference further.
Consistent with practices worldwide, there have
been no ASCTs for breast cancer following 2001, after
studies failed to show a survival benefit in these pa-
tients [16,17].Indications and Diseases
The main indications for allo-HSCT remain acute
leukemias and BMF syndromes. In 2007, allo-HSCT
for BMF syndromes was proportionally a more com-
mon indication for HSCT in the EMBMT data (n 5
106, 15% of allo-HSCT) compared with EBMT
data (n5 523, 5%) [14].Whether this is because of dif-
ferences in the incidence of diseases or other causes re-
mains to be determined, although data on large
cohorts of patients with inherited BMF in the Middle
East have been published [18].
In our survey, hemoglobinopathies were the indica-
tion for allo-HSCT in 874 cases, comprising 15.2% of
all allo-HSCTs. There was considerable variability in
the proportion transplanted for this indication. In
both Iran and Pakistan, hemoglobinopathies were the
indication for allo-HSCT in 30% of all transplants,
and their respective experiences have been reported
[19,20]. In 2007, 102 of 684 (14.9%) transplants were
performed in the Eastern Mediterranean region for
this indication. In contrast, this was an indication in
only 2.7% of transplants reported to EBMT in 2007
(Table 2) [14].
There has been a worldwide decline in the use of
HSCT for the treatment of CML in first chronic phase
with the advent of imatinib mesylate [15,21,22].
Although this recent reduction is observed in our
survey, it is noteworthy that CML still constituted anindication for allo-HSCTs in 60 (8.7%) cases in
2007 compared with 0.4% for 2007 in the EBMT sur-
vey for that year [14]. This may be partly because of
limited access to tyrosine kinase inhibitors in some
countries, but may also reflect demographic differ-
ences that were not analyzed in this activity survey.Stem Cell Source Trends
The trend toward increased use of PBSC in both
allo-HSCT and ASCT is consistent with practice as
reported by the National Marrow Donor Program
(NMDP) and EBMT activity surveys [23,24]. In our
survey, in 2007, 65% of all allo-HSCTs were PBSC
derived, followed by related BM (25%) and UCB
(4%). PBSCs are logistically less burdensome to pro-
cure and entail a lower likelihood of complications
for donors, obviating the need for general anesthesia.
The increasing trend has not been influenced by evi-
dence to suggest a higher incidence of graft-versus-
host disease [25-27].
Although there has been an increase in the use of
UCB as a stem cell source—a trend observed in Eu-
rope [28]—and although there are established cord
banks in the region, these provide a source of stem cells
in only a minority (2%) of transplantations (Figure 7).
Unrelated donor transplants are exceedingly uncom-
mon in the EMBMT region, and only 2 nonumbilical
cord MUD transplantations have been reported. This
is in marked contrast to data reported to the EBMT,
where in 2007, 4752 HSCT (47%) were performed
with an unrelated donor source (Table 2). Larger fam-
ily sizes and the higher probability of finding an HLA-
matched sibling donor, the possibility of a parent being
a match because of consanguinity and intermarriage,
and the availability of HLA-matched nonsibling re-
lated donors all contribute to reducing the need for
a UCB or MUD transplant [4].
Table 2. Comparison of HSCTActivity Reported to EMBMTand EBMT for 2007
EMBMT—2007 Activity EBMT—2007 Activity
Total first transplantations in 2007 1097 25,563
Population of reporting countries* 383 million 988 million†
Teams 15 613
Allo-HSCT versus ASCT, N (%) 684 versus 413 (63 versus 37) 10,072 versus 15,491 (39 versus 71)
First transplants in 2006 versus 2007, N 1012 versus 1097 25,050 versus 25,563
 % increase 8% 2%
 ASCT 2006 versus 2007, N (% rise) 330 versus 413 (25%) 15,389 versus 15,491 (1%)
 Allo-HSCT 2006 versus 2007, N (% rise) 682 versus 684 (0.2%) 9661 versus 10,072 (4%)
Indications, Allo-HSCT, N (%)
 Acute leukemia 289 (42%) 5050 (50%)
 CML 60 (8.7%) 434 (0.4%)
 BMF—all 106 (15.5%) 523 (5.2%)
 Hemoglobinopathy 102 (15%) 254 (2.5%)
 Others
Indications—ASCT, N (% of ASCT)
 Myeloma 110 (26.6%) 6234 (40%)
 HD 128 (30.9%) 1830 (11.8%)
 NHL 103 (24.9%) 4639 (29.9%)
 Solid tumors 27 (6.5%) 1425 (9.2%)
Conditioning in allo-HSCT (includes second transplantations)
Conventional, N (%) 347 (50.7%) 64%
RIC N (%) 51 (7.4%) 36%
Unknown, N (%) 286 (41.8%)
Stem cell source in allo-HSCT, N (%)
BM related 156 (24.8%) 1382 (13.7%)
PB related 408 (64.8%) 3889 (38.6%)
UCB 28 (4.4%) 585 (6%)
MUD 1 (0.1%) 4216 (42%)
Unknown 54 (7.9%)
ASCT indicates autologous hematopoietic stem cell transplantation; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; CML, chronic my-
eloid leukemia; BMF, bone marrow failure; HD, Hodgkin’s disease; NHL, non-Hodgkin lymphoma; RIC, reduced-intensity conditioning; BM, bone mar-
row; PB, peripheral blood; UCB, umbilical cord blood; MUD, matched unrelated donor.
*Countries that reported to both registries for the year include Iran, Saudi Arabia, Tunisia, and Lebanon.
†Includes 106 million population from Iran, Saudi Arabia, Tunisia, and Lebanon.
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Although complete data pertaining to conditioning
were lacking, most of the reported allo-HSCTs were
performed with conventional conditioning, with RIC
being used in no more than 20% of transplantations
in any given year. In contrast, the EBMT survey dem-
onstrated that RIC was utilized in 36% of all allo-
HSCT in 2007, and is reportedly as high as 71% in
some European countries [14,22]. The increase RIC
HSCT in our survey in the years between 1999 and
2001 corresponds temporally to a similar rise in this
practice as reported to EBMT, although the numbers
in our survey are smaller. Data regarding the
indications for RIC transplantations per se were not
requested in our survey. Further studies, including
demographic information regarding the age and/or
comorbidites of patients, may help in elucidating the
reason for this discrepancy between EBMT and
EMBMT data with regard to RIC allo-HSCT. The
disparity may also be a reflection of the differences in
proportions of indications for HSCT in the registries.
CONCLUSIONS
This report demonstrates the unique transplantation
practices for a region where transplant numbers con-tinue to rise.We also demonstrate that there is a marked
difference in transplantation indications as reported to
EMBMT compared with data reported to EBMT with
relatively larger proportions of stem cell transplantations
being performed for hemoglobinopathies and bonemar-
row failure syndromes in the former. Further retrospec-
tive studies focusing on these conditions may be
a valuable contribution of the EMBMT to the interna-
tional HSCT community. A further contrast that re-
quires study is the higher proportion of allo-HSCT
versusASCT, and reducedutilizationof alternate donors
and of RIC transplantations, although data for the latter
was incomplete.The current surveydid not studypatient
demographicsoroutcomes, as thesedatawerenot sought
for the purposes of this activity survey. It is important to
note that because a number of countries comprising the
EMBMT reported to EBMT (Iran, KSA, Lebanon,
Tunisia) and CIBMTR (Egypt, Iran, Pakistan, Saudi
Arabia) in 2007, differences in HSCT activity between
the registries, while reflecting regional differences, rep-
resent data as made available to the registries.
The increasing rates of transplantation will require
adequate planning for resources in the future, not least
with regard to ensuring adequate numbers of trans-
plantation physicians and nurses to deal with increas-
ing transplant demands [29].
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